The decalogue of the 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society consensus document on catheter and surgical ablation of atrial fibrillation
Stylianos Tzeis, Alireza Sepehri Shamloo
Abstract
The 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society consensus statement on catheter and surgical ablation of atrial fibrillation (AF) summarizes recent clinical trial data and technological advancements in AF ablation.1 It also provides updated clinical guidance for managing patients undergoing AF ablation. The following decalogue outlines the key changes included in this joint document (Figure 1). ... Randomized controlled clinical trials (RCTs) have documented that catheter ablation is superior to antiarrhythmic drugs (AADs) in preventing arrhythmia recurrences, improving patients’ symptoms and delaying AF progression to more advanced forms in symptomatic, AAD-naïve patients with recurrent paroxysmal AF, with a similar risk of adverse events. Therefore, catheter ablation should be preferred over AADs as first-line rhythm control therapy in this patient category.